TPVG:NYSETriplePoint Venture Growth BDC Corp. Analysis
Data as of 2026-08-02 - not real-time
$4.52
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TPVG is trading at $4.52, which sits below its 20‑day SMA of $4.63 and well under the 50‑day SMA of $5.00, indicating short‑term weakness, while the 200‑day SMA sits at $5.58, reinforcing a longer‑term bearish bias. The RSI of 40.7 suggests the stock is not yet oversold, and the MACD line is marginally above its signal, offering a faint bullish hint, but the overall trend remains bearish with decreasing volume and a 30‑day volatility of 34%. Market sentiment is at an "Extreme Greed" level (92.88 on the Fear & Greed Index), yet the stock faces a max drawdown of nearly 36% and a beta below 1, pointing to heightened downside risk in a choppy environment.
Fundamentally, the company’s PE of 4.3 versus an industry average of 18 signals a deep value appearance, complemented by a low price‑to‑book of 0.52, but the DCF‑derived fair value of $0.69 is dramatically below the market price, implying overvaluation. A dividend yield of 20.8% looks attractive, but a payout ratio of 96% on thin operating cash flow (‑$58.5M) and a debt‑to‑equity of 127 raise serious sustainability concerns. The balance sheet’s $446M debt versus $8.6M cash and modest free cash flow of $34M further underscore financial strain, making the dividend and valuation outlook precarious despite the high yield.
Fundamentally, the company’s PE of 4.3 versus an industry average of 18 signals a deep value appearance, complemented by a low price‑to‑book of 0.52, but the DCF‑derived fair value of $0.69 is dramatically below the market price, implying overvaluation. A dividend yield of 20.8% looks attractive, but a payout ratio of 96% on thin operating cash flow (‑$58.5M) and a debt‑to‑equity of 127 raise serious sustainability concerns. The balance sheet’s $446M debt versus $8.6M cash and modest free cash flow of $34M further underscore financial strain, making the dividend and valuation outlook precarious despite the high yield.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price below key moving averages and bearish trend direction
- DCF fair value far below market price indicating overvaluation
- Unsustainable dividend payout amid negative operating cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential price correction narrowing valuation gap
- High dividend yield may retain income‑focused investors
- Volatility remains elevated, limiting upside confidence
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Exposure to venture‑stage growth sectors could improve earnings
- Heavy leverage and debt‑to‑equity ratio pose ongoing balance‑sheet risk
- Dividend sustainability concerns may erode total return over time
Key Metrics & Analysis
Financial Health
Revenue Growth1.40%
Profit Margin47.08%
P/E Ratio4.3
ROE12.23%
ROA5.57%
Debt/Equity127.12
P/B Ratio0.5
Op. Cash Flow$-58531000
Free Cash Flow$34.2M
Industry P/E18.0
Technical Analysis
TrendBearish
RSI40.7
Support$4.39
Resistance$4.95
MA 20$4.63
MA 50$5.00
MA 200$5.58
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair Value$0.69
Target Price$6.00
Upside/Downside32.74%
GradeOvervalued
TypeValue
Dividend Yield20.80%
Risk Assessment
Beta0.68
Volatility34.24%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.